Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners
April 01, 2010
Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners
The first portion of the study was completed a few weeks ago, according to a company official, and the drug has been shown to be safe and well tolerated.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sylentis Preps to Move Glaucoma Drug into Phase II Next Year
July 5, 2012 / Gene Silencing News - Sylentis Picks up Option to Alnylam RNAi IP
November 17, 2011 / Gene Silencing News - Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September
August 20, 2009 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Sylentis, Quark, NIH, and More
June 14, 2012 / Gene Silencing News - RXi Cleared to Begin Phase I Testing of Anti-Scarring Drug
May 31, 2012 / Gene Silencing News